168 related articles for article (PubMed ID: 12875941)
21. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
Georgantzi K; Sköldenberg EG; Stridsberg M; Kogner P; Jakobson Å; Janson ET; Christofferson RHB
Pediatr Hematol Oncol; 2018 Mar; 35(2):156-165. PubMed ID: 29737901
[TBL] [Abstract][Full Text] [Related]
22. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
23. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings.
Giovanella L; La Rosa S; Ceriani L; Uccella S; Erba P; Garancini S
Int J Biol Markers; 1999; 14(3):160-6. PubMed ID: 10569138
[TBL] [Abstract][Full Text] [Related]
24. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Dittadi R; Gion M
Clin Biochem; 2013 Aug; 46(12):1145. PubMed ID: 23608355
[No Abstract] [Full Text] [Related]
25. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
[TBL] [Abstract][Full Text] [Related]
26. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
27. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Braga F; Ferraro S; Mozzi R; Dolci A; Panteghini M
Clin Biochem; 2013 Jan; 46(1-2):148-51. PubMed ID: 23000312
[TBL] [Abstract][Full Text] [Related]
28. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
Bajetta E; Ferrari L; Martinetti A; Celio L; Procopio G; Artale S; Zilembo N; Di Bartolomeo M; Seregni E; Bombardieri E
Cancer; 1999 Sep; 86(5):858-65. PubMed ID: 10463986
[TBL] [Abstract][Full Text] [Related]
29. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM
Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
31. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors.
Hernes EH; Linja M; Fosså SD; Visakorpi T; Berner A; Winderen M; Koivisto PA
BJU Int; 2000 Aug; 86(3):240-7. PubMed ID: 10930923
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
Kečkéš Š; Palaj J; Waczulíková I; Dyttert D; Mojtová E; Kováč G; Durdík Š
In Vivo; 2021; 35(5):2863-2868. PubMed ID: 34410979
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
34. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract][Full Text] [Related]
35. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.
Johnson PW; Joel SP; Love S; Butcher M; Pandian MR; Squires L; Wrigley PF; Slevin ML
Br J Cancer; 1993 Apr; 67(4):760-6. PubMed ID: 8385978
[TBL] [Abstract][Full Text] [Related]
36. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
37. [Usefulness of chromogranin A determination in the diagnosis of neuroendocrine neoplasia].
Militello C; Cannizzaro R; Pradella P; Volpin E; Spirch S; Buonadonna A; De Appollonia L; Rossi C; Sigon R; Cipresso S; Terranova O
Chir Ital; 1999; 51(1):45-51. PubMed ID: 10514916
[TBL] [Abstract][Full Text] [Related]
38. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO
J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
40. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
